Form 4: Eli Lilly Director Acquires Shares Through Deferral Plan

Director Juan R. Luciano acquired 16 shares of Eli Lilly common stock at $950.46 per share through a deferral plan.

Summary

• Director Juan R. Luciano acquired 16 shares of Eli Lilly common stock on July 15, 2024.
• The shares were acquired at a price of $950.46 per share.
• The acquisition was made through the Lilly Directors' Deferral Plan.
• The shares are deferred in lieu of cash compensation and will be settled in shares of common stock after the director's separation from service.
• Following the transaction, the director's total holdings are 15,754 shares.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction, which is generally positive as it shows director alignment with company performance. There is no indication of any negative sentiment.

Positives

• The acquisition of shares by a director can be seen as a positive sign of confidence in the company's future.

Future Outlook

The acquired shares will be settled in common stock following the director's separation from service.

Industry Context

This is a routine filing related to director compensation and is common practice for publicly traded companies.

Comparison to Industry Standards

• Director share acquisitions through deferral plans are a common practice among large publicly traded companies, including pharmaceutical companies like Pfizer (PFE) and Merck (MRK).
• These plans are often used to align the interests of directors with those of shareholders by providing long-term equity incentives.
• The specific terms of deferral plans can vary, but the general concept of deferring compensation into stock units is widely used.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders as it aligns director interests with company performance.

Key Dates

Keywords

Eli Lilly, Director, Share Acquisition, Deferral Plan, Stock Units, Insider Trading, LLY